Matches in SemOpenAlex for { <https://semopenalex.org/work/W2568397713> ?p ?o ?g. }
Showing items 1 to 68 of
68
with 100 items per page.
- W2568397713 abstract "Abstract Non-myeloablative conditioning has extended the use of allogeneic hematopoietic transplant to many previously ineligible patients but has to date been disappointing in patients with advanced acute myelogenous leukemia (AML). We added the immunosuppressive and antitumor agent sirolimus (rapamycin) to an established transplant regimen of fludarabine 25 mg/M2 days -7 through -3 and cyclophosphamide 1000mg/M2 days −7 and −6, with tacrolimus and methotrexate immunoprophyllaxis. 23 patients with AML were treated, with median age 59 (range 28–72) at transplant. 6 patients received matched sibling, 11–unrelated donor, 1–5/6 matched and 5-haploidentical (“haplo” −3/6 or 4/6 matched) transplants. The haplo recipients also received antithymocyte globulin on days −1, 1, 3, and 5. Only 7 patients in total were in CR, but all of these were at high risk for relapse because of prior MDS, chromosome status, or other features. 9 patients were in chemotherapy refractory progression, and 7 were primarily refractory to induction therapy. All patients engrafted. In patients without graft versus host disease by day 30 (9 patients) tacrolimus was discontinued between days 45 and 100 while sirolimus was continued. 12/23 patients survive at 61–903 days of followup post transplant (median 525) and 11/12 survivors are currently free of detectable leukemia. 3 of these 12 relapsed at 83, 88, and 243 days, but the first 2 of these have received chemotherapy and DLI and are in CR 771 and 311 days from relapse. The figure below shows overall and progression free survival (PFS). All survivors but the single patient undergoing therapy for progression have performance status 0 or 1 and are free of need for transfusion. 9/12 survivors continue on sirolimus therapy. Only 2 patients, both recipients of haploidentical cells, have died from transplant related causes. Non-myeloablative hematopoietic cell transplantation with sirolimus (rapamycin) based immunosuppression effectively treats many patients with advanced and poor prognosis AML. Given the very limited anti-leukemic activity of the conditioning chemotherapy, this suggests that disease control has been via graft versus leukemic effects alone or combined with anti-leukemic activity of the sirolimus. Figure Figure" @default.
- W2568397713 created "2017-01-13" @default.
- W2568397713 creator A5004302802 @default.
- W2568397713 creator A5059838967 @default.
- W2568397713 creator A5076439728 @default.
- W2568397713 date "2004-11-16" @default.
- W2568397713 modified "2023-10-17" @default.
- W2568397713 title "Successful Treatment of Advanced and Refractory AML with Sirolimus Based Non-Myeloablative Allogeneic Stem Cell Transplantation." @default.
- W2568397713 doi "https://doi.org/10.1182/blood.v104.11.2760.2760" @default.
- W2568397713 hasPublicationYear "2004" @default.
- W2568397713 type Work @default.
- W2568397713 sameAs 2568397713 @default.
- W2568397713 citedByCount "0" @default.
- W2568397713 crossrefType "journal-article" @default.
- W2568397713 hasAuthorship W2568397713A5004302802 @default.
- W2568397713 hasAuthorship W2568397713A5059838967 @default.
- W2568397713 hasAuthorship W2568397713A5076439728 @default.
- W2568397713 hasConcept C121332964 @default.
- W2568397713 hasConcept C126322002 @default.
- W2568397713 hasConcept C141071460 @default.
- W2568397713 hasConcept C142424586 @default.
- W2568397713 hasConcept C2776694085 @default.
- W2568397713 hasConcept C2776755627 @default.
- W2568397713 hasConcept C2777408962 @default.
- W2568397713 hasConcept C2777921159 @default.
- W2568397713 hasConcept C2779263901 @default.
- W2568397713 hasConcept C2779972918 @default.
- W2568397713 hasConcept C2780611847 @default.
- W2568397713 hasConcept C2781059491 @default.
- W2568397713 hasConcept C2909675724 @default.
- W2568397713 hasConcept C2911091166 @default.
- W2568397713 hasConcept C71924100 @default.
- W2568397713 hasConcept C87355193 @default.
- W2568397713 hasConcept C90924648 @default.
- W2568397713 hasConceptScore W2568397713C121332964 @default.
- W2568397713 hasConceptScore W2568397713C126322002 @default.
- W2568397713 hasConceptScore W2568397713C141071460 @default.
- W2568397713 hasConceptScore W2568397713C142424586 @default.
- W2568397713 hasConceptScore W2568397713C2776694085 @default.
- W2568397713 hasConceptScore W2568397713C2776755627 @default.
- W2568397713 hasConceptScore W2568397713C2777408962 @default.
- W2568397713 hasConceptScore W2568397713C2777921159 @default.
- W2568397713 hasConceptScore W2568397713C2779263901 @default.
- W2568397713 hasConceptScore W2568397713C2779972918 @default.
- W2568397713 hasConceptScore W2568397713C2780611847 @default.
- W2568397713 hasConceptScore W2568397713C2781059491 @default.
- W2568397713 hasConceptScore W2568397713C2909675724 @default.
- W2568397713 hasConceptScore W2568397713C2911091166 @default.
- W2568397713 hasConceptScore W2568397713C71924100 @default.
- W2568397713 hasConceptScore W2568397713C87355193 @default.
- W2568397713 hasConceptScore W2568397713C90924648 @default.
- W2568397713 hasLocation W25683977131 @default.
- W2568397713 hasOpenAccess W2568397713 @default.
- W2568397713 hasPrimaryLocation W25683977131 @default.
- W2568397713 hasRelatedWork W1955322177 @default.
- W2568397713 hasRelatedWork W1972184826 @default.
- W2568397713 hasRelatedWork W2023977670 @default.
- W2568397713 hasRelatedWork W2495201617 @default.
- W2568397713 hasRelatedWork W2505492819 @default.
- W2568397713 hasRelatedWork W2560664961 @default.
- W2568397713 hasRelatedWork W2593968947 @default.
- W2568397713 hasRelatedWork W2766769088 @default.
- W2568397713 hasRelatedWork W3001261600 @default.
- W2568397713 hasRelatedWork W3126729473 @default.
- W2568397713 isParatext "false" @default.
- W2568397713 isRetracted "false" @default.
- W2568397713 magId "2568397713" @default.
- W2568397713 workType "article" @default.